Stockscreener 앱 받기
10.28
6.64%
0.64
전일 마감가:
$9.64
열려 있는:
$10.09
하루 거래량:
2.63M
Relative Volume:
1.71
시가총액:
$744.02M
수익:
-
순이익/손실:
$84.01M
주가수익비율:
12.01
EPS:
0.856
순현금흐름:
$-101.16M
1주 성능:
+0.98%
1개월 성능:
-12.14%
6개월 성능:
+12.23%
1년 성능:
+219.25%
1일 변동 폭
$9.75
$10.42
1주일 범위
$6.7023
$10.42
52주 변동 폭
$2.95
$17.65
Omeros Corp Stock (OMER) Company Profile
명칭
Omeros Corp
전화
206-676-5000
주소
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OMER
Omeros Corp
|
10.28 | 744.02M | 0 | 84.01M | -101.16M | 0.856 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Omeros Corp Stock (OMER) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-10 | 개시 | H.C. Wainwright | Buy |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
| 2022-12-08 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-11-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-06-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-10-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2021-10-01 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-09-27 | 개시 | JP Morgan | Neutral |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-08-21 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-14 | 재확인 | Maxim Group | Buy |
| 2019-05-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-12 | 개시 | Seaport Global Securities | Buy |
| 2018-03-23 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-03-05 | 다운그레이드 | Needham | Buy → Hold |
| 2017-11-08 | 개시 | H.C. Wainwright | Buy |
| 2017-05-11 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | 재확인 | Maxim Group | Buy |
| 2017-03-17 | 재확인 | Needham | Buy |
| 2016-11-16 | 재확인 | Wedbush | Outperform |
| 2016-11-10 | 재확인 | Needham | Buy |
| 2016-08-10 | 재확인 | Maxim Group | Buy |
| 2016-06-03 | 개시 | Cantor Fitzgerald | Buy |
| 2016-03-02 | 재확인 | Needham | Buy |
| 2016-02-29 | 재확인 | Wedbush | Outperform |
| 2015-11-11 | 재확인 | Needham | Buy |
| 2015-08-18 | 재확인 | WBB Securities | Strong Buy |
| 2015-08-10 | 개시 | ROTH Capital | Buy |
모두보기
Omeros Corp 주식(OMER)의 최신 뉴스
OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism - Stocktwits
Omeros Corp Annual Shareholders Meeting Transcript - GuruFocus
Omeros StockShares hold above 200-day line after recent rally - AD HOC NEWS
Omeros to repurchase up to $16 million in convertible notes in private deals - Investing.com
Omeros agrees to repurchase up to $16M of 9.50% convertible notes for up to $34M - TradingView
Omeros (NASDAQ: OMER) plans $16.0M buyback of 9.50% 2029 convertible notes - Stock Titan
Omeros Corp (OMER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Omeros Corp (OMER) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Omeros Corp (OMER) Valuation: PE, PB & Fair Value Analysis - TradingKey
Omeros Corp (OMER) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Omeros Corp (OMER) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Omeros Corp (OMER) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Omeros Corp (OMER) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
How Omeros shareholders can join the June 18 virtual annual meeting - Stock Titan
OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment - Stocktwits
OMER Stock Slides As Volatility Grabs Traders’ Attention - StocksToTrade
OMER Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
H.C. Wainwright reiterates Omeros stock rating at buy, $40 target - Investing.com
H.C. Wainwright reiterates Omeros stock rating at buy, $40 target By Investing.com - Investing.com Australia
Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now - Yahoo Finance
OMER Technical Analysis | Trend, Signals & Chart Patterns | OMEROS CORP (NASDAQ:OMER) - ChartMill
OMER Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Omeros: Launch Traction Encouraging, But Risk/Reward Looks Balanced (Initiating Hold) - Seeking Alpha
Omeros (OMER) Q4 2025 Earnings Transcript - AOL.com
OMER Stock Chart | OMEROS CORP (NASDAQ:OMER) - ChartMill
Omeros Corp director Cable sells $87,039 in stock By Investing.com - Investing.com Australia
Omeros Corp director Cable sells $87,039 in stock - Investing.com
Omeros (NASDAQ: OMER) director exercises options and sells 7,500 shares under 10b5-1 plan - Stock Titan
Why Omeros Stock Is Sliding Today Even as Biotech Shares Climb - Bez Kabli
OMER Technical Analysis & Stock Price Forecast - Intellectia AI
Why did Omeros stock jump 5% in after-hours trading today? - MSN
[144] OMEROS CORP SEC Filing - Stock Titan
Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA - MSN
Earnings call transcript: Omeros Q1 2026: Stock dips after earnings miss - Investing.com
Earnings call transcript: Omeros Q1 2026: Stock dips after earnings miss By Investing.com - Investing.com Canada
Omeros’ $100 Million Buyback Plan Heightens Volatility and Valuation Risk for Shareholders - The Globe and Mail
Seattle InnoSEngine headed to Bothell I An update on Omeros - The Business Journals
Omeros Corporation (NASDAQ:OMER) Q1 2026 Earnings Call Transcript - Insider Monkey
Omeros (OMER) Q1 2026 Earnings Transcript - The Globe and Mail
Omeros Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Omeros (OMER) Reports Strong Q1 2026 Earnings and Positive Cash Flow from YARTEMLEA - GuruFocus
Omeros Corp (OMER) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):